Parkinson’s Treatment Report

www.ParkinsonsTreatmentReport.com

Opicapone

Neurocrine Biosciences to Present Data on Opicapone at the 2019 World Congress on Parkinson’s Disease and Related Disorders

https://www.prnewswire.com/news-releases/neurocrine-biosciences-to-present-data-on-ingrezza-valbenazine-and-opicapone-at-the-2019-world-congress-on-parkinsons-disease-and-related-disorders-300865804.html

Neurocrine Biosciences to Present Data on INGREZZA® (valbenazine) and Opicapone at the 2019 World Congress on Parkinson’s Disease and Related Disorders

– INGREZZA Data from Long-Term Phase III Studies Support Sustained Clinical Benefit, Safety and Tolerability in Patients with Tardive Dyskinesia

– Pooled Analyses of Two Pivotal Studies Showed Opicapone Reduced OFF Time and Was Generally Well Tolerated in More than 500 Patients with Parkinson’s Disease and Motor Fluctuations

Neurocrine Biosciences Presents Phase III Data Analysis Demonstrating that Opicapone Added to Levodopa Resulted in a Significant and Sustained Increase in ON Time without Troublesome Dyskinesia in Parkinson’s Disease Patients

https://www.biospace.com/article/neurocrine-biosciences-presents-phase-iii-data-analysis-demonstrating-that-opicapone-added-to-levodopa-resulted-in-a-significant-and-sustained-increase-in-on-time-without-troublesome-dyskinesia-in-parkinson-s-disease-patients/

Neurocrine Biosciences Presents Phase III Data Analysis Demonstrating that Opicapone Added to Levodopa Resulted in a Significant and Sustained Increase in ON Time without Troublesome Dyskinesia in Parkinson’s Disease Patients